Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The benefit of reduced mortality must be balanced against the harms of overdiagnosis.
It was 27% more accurate than the standard approach at detecting any metastases.
Here’s a list of the approved drugs to treat prostate cancer. Click on any of the medications for more info on dosing, side effects a...
Gavin Ha, PhD, receives grant to study whether noninvasive procedure can help monitor and predict how patients will respond to therapy
Men who took Zytiga had higher quality of life scores and less pain than those treated with chemotherapy.
The personalized vaccine was associated with a 45% lower risk of death in a real-world study.
The drug was previously approved for castration-resistant prostate cancer.
First targeted therapy may prolong survival of men with advanced prostate cancer.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
Building on this discovery, researchers have designed a new treatment that showed promise in a study of mice.
Researchers are continuing to identify potential biomarkers or specific clinical factors to identify the best candidates for treatments.
These men lived for a median of 30 months compared to 26 months for white men.
The benefits? Risk is assessed more rapidly and at a cheaper cost.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.